PolyPeptide Group AG (PPGN.SW) on Monday reported preliminary results for the 2025 financial year, showing higher revenue and improved profitability compared with 2024. The company generated revenue of approximately EUR 389 million, representing an increase of about 15.6 percent, mainly supported by demand for metabolic therapeutics. The EBITDA margin improved to an estimated 11 to 12 percent, up from 7.5 percent a year earlier.
Capital expenditures were just over EUR 100 million, in line with expectations. PolyPeptide ended the year with EUR 75 million in cash and EUR 51 million available under its revolving credit facility. PPGN.SW closed Monday's trading at CHF 31.15 up CHF 2.85 or 10.07 percent on the SIX Swiss Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.